{"id":9748,"date":"2023-08-07T13:28:25","date_gmt":"2023-08-07T13:28:25","guid":{"rendered":"https:\/\/isafespend.com\/investing\/lupin-pharmaceuticals-just-recalled-two-birth-control-pills\/"},"modified":"2023-08-07T13:28:26","modified_gmt":"2023-08-07T13:28:26","slug":"lupin-pharmaceuticals-just-recalled-two-birth-control-pills","status":"publish","type":"post","link":"https:\/\/isafespend.com\/?p=9748","title":{"rendered":"Lupin Pharmaceuticals Just Recalled Two Birth Control Pills"},"content":{"rendered":"<div>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">Key Takeaways<\/h2>\n<ul>\n<li>Lupin Pharmaceuticals has recalled two batches of its Tydemy birth control pills after reporting defects<\/li>\n<li>The company\u2019s earnings beat reported higher profits and revenues<\/li>\n<li>Lupin\u2019s share price rose 4% at the earnings news and has increased 47% in 2023<\/li>\n<\/ul>\n<p>One of the most prominent players in the U.S. pharmaceutical industry has had to recall two batches of its birth control pills after finding they were defective. Lupin Pharmaceuticals has asked any retailers and distributors of Tydemy to stop selling the bad batches immediately and has advised those taking the pills to seek medical advice.<\/p>\n<p>Despite the hiccup, Lupin\u2019s earnings beat was enough to keep investors on side, and the share price saw a lift. Indian pharmaceuticals have outpaced their U.S. peers on the markets so far in 2023 &#8211; let\u2019s take a look at the details.<\/p>\n<p><em>Lupin\u2019s share price is a bright spot in the otherwise ailing pharmaceutical sector, but you can\u2019t make any guarantees for individual stock picking. Diversify your portfolio with Q.ai\u2019s <\/em><em data-ga-track=\"ExternalLink:https:\/\/learn.tryq.ai\/blog\/foundation-investment-kits?utm_campaign=Forbes&amp;utm_medium=article&amp;utm_source=Forbes\">Foundation Kits<\/em><em>, which bundle together different assets in themed packages like tech and global trends.<\/em><\/p>\n<p><fbs-ad position=\"inread\" progressive=\"\" ad-id=\"article-0-inread\" aria-hidden=\"true\" role=\"presentation\"><\/fbs-ad><\/p>\n<p><em>The secret weapon for helping to supercharge your returns is a sophisticated AI algorithm that works tirelessly behind the scenes to dig through the data, predict which assets are set to perform and adjust each Kit\u2019s holdings accordingly. It\u2019s all in the name of helping your money work harder.<\/em><\/p>\n<p><em data-ga-track=\"ExternalLink:https:\/\/refer.tryq.ai\/oGxdk7ZzZBb\">Download Q.ai today <\/em><em>for access to AI-powered investment strategies.<\/em><\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">Why did Lupin recall birth control pills?<\/h2>\n<p>Lupin Pharmaceuticals, the U.S. arm of Indian pharmaceutical giant Lupin Ltd., has voluntarily recalled two Tydemy birth control pill batches. The reason was that the pills in question tested low for ascorbic acid and high for a \u201cknown impurity\u201d, which reduces the overall effectiveness of the medication and could result in an unexpected pregnancy. The impurity wasn\u2019t named.<\/p>\n<p>The two batches were distributed in the U.S. between June 3, 2022 and May 31, 2023. In a statement, Lupin said it was notifying wholesalers and distributors about the recall. Anyone taking the drug\u2019s impacted batches is advised to continue taking the medication and seek medical advice immediately to find alternative contraceptive methods.<\/p>\n<p>The pharmaceutical has an unfortunate recent history of product recalls. In November last year, Lupin received a warning letter from the FDA at its active pharmaceutical ingredients plant in India. It was the fourth warning Lupin had received in nine weeks.<\/p>\n<p>That same month also saw Lupin forced to suspend U.S. drug production from another of its India-based plants, with the FDA asking Lupin to let them know \u201cbefore resuming operations\u201d.<\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">How did Lupin\u2019s earnings beat go?<\/h2>\n<p>It was a bumper profit crop for Lupin\u2019s latest earnings report, delivered late last week. The pharmaceutical giant made a consolidated net profit of INR 453.33 crore ($54.78 million) for its first quarter, compared to last year\u2019s Q1 result of a consolidated net loss of INR 86.82 crore ($10.49 million).<\/p>\n<p>The revenue total for its first quarter operations was 4,814 crore ($581,741), up around 29% from last year\u2019s Q1 figure of INR 3,744 crore ($452,438). The U.S. business arm grew 57%, contributing 34% of total revenue.<\/p>\n<p>Analysts put Lupin\u2019s financial turnaround down to the company launching three new products in the quarter, including two nasal sprays, and securing four new drug approvals from the FDA. In the filing, Lupin\u2019s managing director, Nilesh Gupta, said the company expects to see more U.S. drug approvals that will \u201chelp sustain the growth momentum both in the top line and bottom line as we move ahead\u201d.<\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">Lupin\u2019s stock performance in 2023<\/h2>\n<p>Investors were apparently unphased by the birth control pills recall, as the positive earnings beat eclipsed the bad news. Lupin Ltd., listed on the National Stock Exchange of India, saw a 4% rise in its share price on Friday, hitting a new 52-week high of INR 1,078 ($13.02). The shares have seen a further 1.6% gain during Monday trading.<\/p>\n<p>Despite the recalls and FDA warnings, Lupin\u2019s share price has gained 47% since the start of the year, far outperforming its rivals. India-headquartered Sun Pharmaceuticals has seen a 16.5% gain in the same period, while pharma conglomerate Cipla has climbed 14.1%.<\/p>\n<p>The Indian pharmaceutical sector is performing entirely differently on the stock market than U.S. peers, who have struggled after becoming the pandemic heroes. Pfizer\u2019s share price has plunged 31% in value while Moderna has declined by 39%; AstraZeneca has stayed flat on the Nasdaq after some peaks and troughs throughout 2023.<\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">How is the broader pharmaceutical industry faring?<\/h2>\n<p>It\u2019s been a challenging year so far for Big Pharma, with the current earnings season reflecting the big companies\u2019 struggle to bounce back after the pandemic. Pfizer reported second-quarter sales that missed Wall Street estimates and cut its full-year guidance at the same time. The anticipates headwinds from a reduced sales forecast for its new respiratory illness vaccine and lowered output thanks to tornado damage to a critical manufacturing plant. Pfizer\u2019s CFO, David Denton, acknowledged the issues as \u201cnear-term revenue challenges\u201d.<\/p>\n<p>Moderna actually raised its forecast for Covid vaccine sales, which is its only approved product, saying it now expects to make between $6-8 billion with full-year sales with its pending fall release of an updated Covid jab. Revenue was up for the second quarter, hitting $344 million versus the $308 million forecasted, but there are still concerns over the company\u2019s long-term profitability.<\/p>\n<p>M&amp;A activity in the sector is also picking up. Biogen recently announced that it\u2019s buying Reata Pharmaceuticals for $7.3 billion to get its hands on the company\u2019s landmark new treatment for a rare neuromuscular disease. Under the deal, Biogen will pay $172.50 per share in cash; Reata\u2019s share price skyrocketed 51% at the news to hit $165.<\/p>\n<p>Telemedicine has also seen some movement in the form of Amazon rolling out its new virtual Amazon Clinics nationwide in a bid to finally break into the healthcare market. The tech titan recently completed its $3.9 billion acquisition of OneMedical earlier this year and has its own Amazon Pharmacy option on the website, so we\u2019d say it\u2019s a pretty serious attempt at capturing market share.<\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">The bottom line<\/h2>\n<p>The birth control pills recall is bad news for consumers, but Lupin Pharmaceuticals has shrugged off similar recalls in the recent past. The company\u2019s share price wasn\u2019t affected by the news and was bolstered by the better-than-expected earnings beat.<\/p>\n<p>As for the wider pharma industry, it\u2019s shaping up to be a mixed bag bordering on the edge of disappointment. The coming months may bring more mergers and acquisitions news if the drought has ended, but pharmaceutical companies are struggling to pick it up after the bumper pandemic profits.<\/p>\n<p><em>Although Lupin Ltd&#8217;s shares are shining in the struggling pharmaceutical sector, betting on individual stocks can be risky. Broaden your horizons with Q.ai\u2019s <\/em><em data-ga-track=\"ExternalLink:https:\/\/learn.tryq.ai\/blog\/foundation-investment-kits?utm_campaign=Forbes&amp;utm_medium=article&amp;utm_source=Forbes\">Foundation Kits<\/em><em>, offering a well-rounded assortment of assets grouped around themes like tech and international trends. <\/em><\/p>\n<p><em>The hidden ace? An AI algorithm that works day and night to analyze data, forecast top-performing assets and recalibrate the Kits\u2019 holdings, helping to ensure your investment is always in motion.<\/em><\/p>\n<p><em data-ga-track=\"ExternalLink:https:\/\/refer.tryq.ai\/zvdCWOYzZBb\">Download Q.ai today<\/em><em> for access to AI-powered investment strategies.<\/em><\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.forbes.com\/sites\/qai\/2023\/08\/07\/lupin-pharmaceuticals-just-recalled-two-birth-control-pillsdid-it-affect-the-stock\/\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways Lupin Pharmaceuticals has recalled two batches of its Tydemy birth control pills after reporting defects The company\u2019s earnings beat reported higher profits and revenues Lupin\u2019s share price rose 4% at the earnings news and has increased 47% in 2023 One of the most prominent players in the U.S. pharmaceutical industry has had to<\/p>\n","protected":false},"author":1,"featured_media":9749,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[49],"tags":[],"class_list":{"0":"post-9748","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investing"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.12 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Lupin Pharmaceuticals Just Recalled Two Birth Control Pills | iSafeSpend<\/title>\n<meta name=\"description\" content=\"Key Takeaways Lupin Pharmaceuticals has recalled two batches of its Tydemy birth control pills after reporting defects The company\u2019s earnings beat\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/isafespend.com\/?p=9748\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lupin Pharmaceuticals Just Recalled Two Birth Control Pills | iSafeSpend\" \/>\n<meta property=\"og:description\" content=\"Key Takeaways Lupin Pharmaceuticals has recalled two batches of its Tydemy birth control pills after reporting defects The company\u2019s earnings beat\" \/>\n<meta property=\"og:url\" content=\"https:\/\/isafespend.com\/?p=9748\" \/>\n<meta property=\"og:site_name\" content=\"iSafeSpend\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-07T13:28:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-07T13:28:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/isafespend.com\/wp-content\/uploads\/2023\/08\/1691414905_0x0.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"799\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/isafespend.com\/?p=9748#article\",\"isPartOf\":{\"@id\":\"https:\/\/isafespend.com\/?p=9748\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/isafespend.com\/#\/schema\/person\/5b8c1c75336efaf09b163cd1eab0c9bf\"},\"headline\":\"Lupin Pharmaceuticals Just Recalled Two Birth Control Pills\",\"datePublished\":\"2023-08-07T13:28:25+00:00\",\"dateModified\":\"2023-08-07T13:28:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/isafespend.com\/?p=9748\"},\"wordCount\":1207,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/isafespend.com\/#organization\"},\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/isafespend.com\/?p=9748#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/isafespend.com\/?p=9748\",\"url\":\"https:\/\/isafespend.com\/?p=9748\",\"name\":\"Lupin Pharmaceuticals Just Recalled Two Birth Control Pills | iSafeSpend\",\"isPartOf\":{\"@id\":\"https:\/\/isafespend.com\/#website\"},\"datePublished\":\"2023-08-07T13:28:25+00:00\",\"dateModified\":\"2023-08-07T13:28:26+00:00\",\"description\":\"Key Takeaways Lupin Pharmaceuticals has recalled two batches of its Tydemy birth control pills after reporting defects The company\u2019s earnings beat\",\"breadcrumb\":{\"@id\":\"https:\/\/isafespend.com\/?p=9748#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/isafespend.com\/?p=9748\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/isafespend.com\/?p=9748#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/isafespend.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lupin Pharmaceuticals Just Recalled Two Birth Control Pills\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/isafespend.com\/#website\",\"url\":\"https:\/\/isafespend.com\/\",\"name\":\"Solutions For Real\",\"description\":\"Latest Finance News and Updates\",\"publisher\":{\"@id\":\"https:\/\/isafespend.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/isafespend.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/isafespend.com\/#organization\",\"name\":\"Solutions For Real\",\"url\":\"https:\/\/isafespend.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/isafespend.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/isafespend.com\/wp-content\/uploads\/2023\/08\/sf-logo-1.png\",\"contentUrl\":\"https:\/\/isafespend.com\/wp-content\/uploads\/2023\/08\/sf-logo-1.png\",\"width\":690,\"height\":64,\"caption\":\"Solutions For Real\"},\"image\":{\"@id\":\"https:\/\/isafespend.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/isafespend.com\/#\/schema\/person\/5b8c1c75336efaf09b163cd1eab0c9bf\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/isafespend.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/isafespend.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1691264579-96x96.png\",\"contentUrl\":\"https:\/\/isafespend.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1691264579-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/isafespend.com\"],\"url\":\"https:\/\/isafespend.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lupin Pharmaceuticals Just Recalled Two Birth Control Pills | iSafeSpend","description":"Key Takeaways Lupin Pharmaceuticals has recalled two batches of its Tydemy birth control pills after reporting defects The company\u2019s earnings beat","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/isafespend.com\/?p=9748","og_locale":"en_US","og_type":"article","og_title":"Lupin Pharmaceuticals Just Recalled Two Birth Control Pills | iSafeSpend","og_description":"Key Takeaways Lupin Pharmaceuticals has recalled two batches of its Tydemy birth control pills after reporting defects The company\u2019s earnings beat","og_url":"https:\/\/isafespend.com\/?p=9748","og_site_name":"iSafeSpend","article_published_time":"2023-08-07T13:28:25+00:00","article_modified_time":"2023-08-07T13:28:26+00:00","og_image":[{"width":1200,"height":799,"url":"https:\/\/isafespend.com\/wp-content\/uploads\/2023\/08\/1691414905_0x0.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/isafespend.com\/?p=9748#article","isPartOf":{"@id":"https:\/\/isafespend.com\/?p=9748"},"author":{"name":"News Room","@id":"https:\/\/isafespend.com\/#\/schema\/person\/5b8c1c75336efaf09b163cd1eab0c9bf"},"headline":"Lupin Pharmaceuticals Just Recalled Two Birth Control Pills","datePublished":"2023-08-07T13:28:25+00:00","dateModified":"2023-08-07T13:28:26+00:00","mainEntityOfPage":{"@id":"https:\/\/isafespend.com\/?p=9748"},"wordCount":1207,"commentCount":0,"publisher":{"@id":"https:\/\/isafespend.com\/#organization"},"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/isafespend.com\/?p=9748#respond"]}]},{"@type":"WebPage","@id":"https:\/\/isafespend.com\/?p=9748","url":"https:\/\/isafespend.com\/?p=9748","name":"Lupin Pharmaceuticals Just Recalled Two Birth Control Pills | iSafeSpend","isPartOf":{"@id":"https:\/\/isafespend.com\/#website"},"datePublished":"2023-08-07T13:28:25+00:00","dateModified":"2023-08-07T13:28:26+00:00","description":"Key Takeaways Lupin Pharmaceuticals has recalled two batches of its Tydemy birth control pills after reporting defects The company\u2019s earnings beat","breadcrumb":{"@id":"https:\/\/isafespend.com\/?p=9748#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/isafespend.com\/?p=9748"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/isafespend.com\/?p=9748#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/isafespend.com\/"},{"@type":"ListItem","position":2,"name":"Lupin Pharmaceuticals Just Recalled Two Birth Control Pills"}]},{"@type":"WebSite","@id":"https:\/\/isafespend.com\/#website","url":"https:\/\/isafespend.com\/","name":"Solutions For Real","description":"Latest Finance News and Updates","publisher":{"@id":"https:\/\/isafespend.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/isafespend.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/isafespend.com\/#organization","name":"Solutions For Real","url":"https:\/\/isafespend.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/isafespend.com\/#\/schema\/logo\/image\/","url":"https:\/\/isafespend.com\/wp-content\/uploads\/2023\/08\/sf-logo-1.png","contentUrl":"https:\/\/isafespend.com\/wp-content\/uploads\/2023\/08\/sf-logo-1.png","width":690,"height":64,"caption":"Solutions For Real"},"image":{"@id":"https:\/\/isafespend.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/isafespend.com\/#\/schema\/person\/5b8c1c75336efaf09b163cd1eab0c9bf","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/isafespend.com\/#\/schema\/person\/image\/","url":"https:\/\/isafespend.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1691264579-96x96.png","contentUrl":"https:\/\/isafespend.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1691264579-96x96.png","caption":"News Room"},"sameAs":["https:\/\/isafespend.com"],"url":"https:\/\/isafespend.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/isafespend.com\/index.php?rest_route=\/wp\/v2\/posts\/9748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/isafespend.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/isafespend.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/isafespend.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/isafespend.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9748"}],"version-history":[{"count":1,"href":"https:\/\/isafespend.com\/index.php?rest_route=\/wp\/v2\/posts\/9748\/revisions"}],"predecessor-version":[{"id":9750,"href":"https:\/\/isafespend.com\/index.php?rest_route=\/wp\/v2\/posts\/9748\/revisions\/9750"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/isafespend.com\/index.php?rest_route=\/wp\/v2\/media\/9749"}],"wp:attachment":[{"href":"https:\/\/isafespend.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/isafespend.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/isafespend.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}